Privacy Impact Assessments for Biotech & Pharma
Assess and document privacy risks in your programs and systems across Biotech & Pharma.
Biotech and pharmaceutical organizations occupy a category of data sensitivity that few sectors match. Clinical trial participants entrust your organization with health outcomes, treatment responses, and — in genomics and precision medicine — information that is biologically unique to them and their families. That data is collected under ethics board approval and regulatory oversight, with expectations about how it will be used, retained, and accessed. A Privacy Impact Assessment is how you document that those expectations are being met across every system and partnership in your research environment.
The regulatory picture for this sector is layered. Health-sector privacy legislation at the provincial level governs personal health information, including data collected in clinical research settings. PIPEDA applies to commercial activities, and Health Canada oversight introduces compliance obligations around research data integrity and participant protection. For organizations running multinational trials or working with contract research organizations in multiple jurisdictions, the cross-border data governance dimension adds material complexity that a PIA must explicitly address.
The risks are not theoretical. Genomic data cannot be changed if it is exposed — unlike a password, a genetic profile is permanent. Clinical trial participant records, if disclosed, can compromise trial integrity and create significant legal and reputational exposure for the sponsoring organization. Proprietary research data and IP are a high-value target for criminal actors and nation-state espionage, and your CRO and research partner network is an extension of your own attack surface that demands the same rigor you apply internally.
Privacy Horizon works with biotech and pharmaceutical organizations to conduct PIAs that reflect the actual complexity of the research data environment — not a generic template applied to a specialized context. We map data flows across clinical trial management systems, biorepositories, partner CROs, and cloud research infrastructure. We identify where consent scope, secondary use, and cross-border transfer provisions do not align with current data practices, and we produce regulator-ready documentation your data protection officer, ethics board, and legal counsel can rely on when scrutiny comes.
Why Privacy Impact Assessment matters for Biotech & Pharma
Clinical research generates some of the most sensitive personal information recognized in law — and the participants who provide it have a reasonable expectation that it will be handled with precisely the care your ethics board approved. A Privacy Impact Assessment provides documented assurance that this expectation is being met across every system, vendor, and cross-border pathway in your research environment. For biotech and pharma organizations seeking Health Canada approval, building research partnerships, or entering enterprise procurement processes, that documentation is increasingly part of the table stakes — not a discretionary exercise.
Biotech and pharmaceutical organizations handle some of the most sensitive categories of personal information — genetic data, clinical trial records, and health outcomes — alongside high-value intellectual property that is a frequent target of nation-state and criminal threat actors. Regulatory scrutiny spans data protection law, clinical research ethics requirements, and Health Canada oversight. Research partnerships and global trial networks introduce complex cross-border data governance obligations.
Relevant frameworks: ISO 27001, ISO 27701, SOC 2 Type II, Health-sector privacy legislation (PHIPA-type, provincial), PIPEDA / provincial private-sector privacy laws
Our approach for Biotech & Pharma
We start by mapping data flows across the full research lifecycle — participant recruitment and consent, data collection, CRO processing, analysis platforms, and archiving — to build a comprehensive picture of where personal and health information moves and who has access to it. We assess consent scope and secondary-use provisions against the actual data practices in your systems, evaluate cross-border transfer mechanisms for international trial partners, and identify contractual gaps in your CRO and vendor agreements. The PIA deliverable includes a structured risk register, gap analysis against applicable health-sector and private-sector privacy frameworks, and a prioritized mitigation roadmap your team can act on.
What Privacy Impact Assessment includes
A privacy impact assessment (PIA) identifies and mitigates privacy risks before they become problems — and produces the documentation regulators and partners expect.
Data Flow Mapping
Understand how personal information moves through your systems.
Risk Identification
Surface privacy risks early, before launch.
Mitigation Planning
Concrete steps to reduce identified risks.
Regulator-Ready Documentation
Defensible records of your privacy diligence.
Other services for Biotech & Pharma
What's Protecting Your Business from the Next Threat?
Don't wait for a breach to expose your vulnerabilities. Let Privacy Horizon secure your data, ensure compliance, and build lasting trust.